After more than a decade of research, a new-generation CAR-T therapy developed by VHIO, in collaboration with the Hospital del…
UITM-CaixaResearch
Sponsored by F. Hoffmann-La Roche Ltd, in collaboration with Vall d’Hebron Institute of Oncology (VHIO), a first-in-human clinical trial was…
VHIO played a prominent role at the ESMO Targeted Anticancer Therapies (TAT) congress, one of the leading international forums in…
Reported at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany, results from four multicenter early phase…
Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting* by Jaume Capdevila, a Medical Oncologist of the…
VHIO cordinates the EU-funded PragmaTIL project. funded by the EU. The initiative brings together 12 institutions from 6 countries with…
Co-authored by leading experts in oncology, a review article recently published in the Journal of Clinical Oncology (JCO)* provides an…
Published in the journal Nature Communications*, results from a first-in-human, phase I clinical trial of an oral, potent and reversible…
The journal Nature has published the results of a clinical trial led by researchers from the Clínica Universidad de Navarra…
Co-authored by investigators of VHIO’s Cancer Genomics Group and Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch, results…
